M. Lorenzi

First-Line Osimertinib in Patients with <i>EGFR</i>-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

M. Lorenzi, Alessandra Ferro, Fabiana Letizia Cecere et al. · The Oncologist · 2021 · 62 citations · Full text

Medicine, Oncology, Pharmacology +15

Comparison of conservative management and juvenile pubic symphysiodesis in the early treatment of canine hip dysplasia

G. Dravelli, Luca Vezzoni, M. Lorenzi et al. · Veterinary and Comparative Orthopaedics and Traumatology · 2008 · 53 citations

Medicine, Orthopaedic Surgery, Veterinary Clinical Sciences +16

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

Teresa Troiani, Loredana Vecchione, Erika Martinelli et al. · British Journal of Cancer · 2012 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non–small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy

Alessandro Dal Maso, M. Lorenzi, Elisa Roca et al. · Clinical Lung Cancer · 2019 · 26 citations

Medicine, Genetics, Oncology +14

Extraskeletal Myxoid Chondrosarcoma: Clinical and Molecular Characteristics and Outcomes of Patients Treated at Two Institutions

Benedetta Chiusole, Axel Le Cesne, Marco Rastrelli et al. · Frontiers in Oncology · 2020 · 23 citations · Full text

Medicine, Oncology, Pathology +15